Overexpression of CD163 in vitreous and fibrovascular membranes of patients with proliferative diabetic retinopathy: Possible involvement of periostin

British Journal of Ophthalmology

Volumn 99, Issue 4, 2015, Pages 451-456

  Kobayashi, Yoshiyuki ^a   Yoshida, Shigeo ^a   Nakama, Takahito ^a   Zhou, Yedi ^a   Ishikawa, Keijiro ^a   Arita, Ryoichi ^a   Nakao, Shintaro ^a   Miyazaki, Masanori ^a   Sassa, Yukio ^a,b   Oshima, Yuji ^a   Izuhara, Kenji ^c   Kono, Toshihiro ^b   Ishibashi, Tatsuro ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Fukuoka University Chikushi Hospital   (Japan)

^c SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; CD68 ANTIGEN; TRANSCRIPTION FACTOR RUNX2; VASCULOTROPIN; BIOLOGICAL MARKER; CD68 ANTIGEN, HUMAN; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; POSTN PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; EPIRETINAL MEMBRANE; FEMALE; FIBROVASCULAR MEMBRANE; HUMAN; HUMAN TISSUE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; RETINA MACULOPATHY; VITRECTOMY; VITREORETINOPATHY; VITREOUS BODY; AGED; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIRETINAL MEMBRANE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

EID: 84925402892     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-305321     Document Type: Article

References (25)

1. Sivaprasad S, Gupta B, Crosby-Nwaobi R, et al. Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective. Surv Ophthalmol 2012;57:347-70.
2. Yoshida A, Yoshida S, Ishibashi T, et al. Intraocular neovascularization. Histol Histopathol 1999;14:1287-94.
3. Hiscott P, Wong D, Grierson I. Challenges in ophthalmic pathology: the vitreoretinal membrane biopsy. Eye 2000;14:549-59.
4. Simo R, Carrasco E, Garcia-Ramirez M, et al. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2006;2:71-98.
5. Yoshida S, Nakama T, Ishikawa K, et al. Antiangiogenic shift in vitreous after vitrectomy in patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2012;53:6997-7003.
6. Yamaji Y, Yoshida S, Ishikawa K, et al. TEM7 (PLXDC1) in neovascular endothelial cells of fibrovascular membranes from patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2008;49:3151-7.
7. Yoshida S, Ishikawa K, Asato R, et al. Increased expression of periostin in vitreous and fibrovascular membranes obtained from patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2011;52:5670-8.
8. Ishikawa K, Yoshida S, Nakao S, et al. Periostin promotes the generation of fibrous membranes in proliferative vitreoretinopathy. FASEB J 2014;28:131-42.
9. Asato R, Yoshida S, Ogura A, et al. Comparison of gene expression profile of epiretinal membranes obtained from eyes with proliferative vitreoretinopathy to that of secondary epiretinal membranes. PLoS ONE 2013;8:e54191.
10. Snead DR, James S, Snead MP. Pathological changes in the vitreoretinal junction 1: epiretinal membrane formation. Eye 2008;22:1310-17.
11. Sunderkotter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leukoc Biol 1994;55:410-22.
12. Yoshida S, Yoshida A, Ishibashi T, et al. Role of MCP-1 and MIP-1alpha in retinal neovascularization during postischemic inflammation in a mouse model of retinal neovascularization. J Leukoc Biol 2003;73:137-44.
13. Ishikawa K, Yoshida S, Nakao S, et al. Bone marrow-derived monocyte lineage cells recruited by MIP-1beta promote physiological revascularization in mouse model of oxygen-induced retinopathy. Lab Invest 2012;92:91-101.
14. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009;27:451-83.
15. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805-20.
16. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012;122:787-95.
17. Ambarus CA, Krausz S, van Eijk M, et al. Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods 2012;375:196-206.
18. Moller HJ. Soluble CD163. Scand J Clin Lab Inv 2012;72:1-13.
19. Akila P, Prashant V, Suma MN, et al. CD163 and its expanding functional repertoire. Clini Chim Acta 2012;413:669-74.
20. Ishikawa K, Yoshida S, Kadota K, et al. Gene expression profile of hyperoxic and hypoxic retinas in a mouse model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2010;51:4307-19.
21. Shao R, Bao S, Bai X, et al. Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol 2004;24:3992-4003.
22. Pierce EA, Avery RL, Foley ED, et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995;92:905-9.
23. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol 2002;86:363-5.
24. Kuiper EJ, Van Nieuwenhoven FA, de Smet MD, et al. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One 2008;3:e2675.
25. El-Sabagh HA, Abdelghaffar W, Labib AM, et al. Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications. Ophthalmology 2011;118:636-41.